Page 504 - Hematology_ Basic Principles and Practice ( PDFDrive )

424 Part IV Disorders of Hematopoietic Cell Development

3. Rother RP, Rollins SA, Mojcik CF, et al: Discovery and development of 16. Hillmen P, Muus P, Roth A, et al: Long-term safety and efficacy of
the complement inhibitor eculizumab for the treatment of paroxysmal sustained eculizumab treatment in patients with paroxysmal nocturnal
nocturnal hemoglobinuria. Nat Biotechnol 25(11):1256–1264, 2007. haemoglobinuria. Br J Haematol 162(1):62–73, 2013.
4. Krawitz PM, Hochsmann B, Murakami Y, et al: A case of paroxysmal 17. Brodsky RA, Mukhina GL, Li S, et al: Improved detection and char-
nocturnal hemoglobinuria caused by a germline mutation and a somatic acterization of paroxysmal nocturnal hemoglobinuria using fluorescent
mutation in PIGT. Blood 122(7):1312–1315, 2013. aerolysin. Am J Clin Pathol 114(3):459–466, 2000.
5. Johnston JJ, Gropman AL, Sapp JC, et al: The phenotype of a germline 18. Borowitz MJ, Craig FE, DiGiuseppe JA, et al: Guidelines for the diagno-
mutation in PIGA: the gene somatically mutated in paroxysmal noctur- sis and monitoring of paroxysmal nocturnal hemoglobinuria and related
nal hemoglobinuria. Am J Hum Genet 90(2):295–300, 2012. disorders by flow cytometry. Cytometry B Clin Cytom 78(4):211–230,
6. Belet S, Fieremans N, Yuan X, et al: Early frameshift mutation in PIGA 2010.
identified in a large XLID family without neonatal lethality. Hum Mutat 19. Hillmen P, Young NS, Schubert J, et al: The complement inhibitor
35(3):350–355, 2014. eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med
7. Oni SB, Osunkoya BO, Luzzatto L: Paroxysmal nocturnal hemoglo- 355:1233–1243, 2006.
binuria: evidence for monoclonal origin of abnormal red cells. Blood 20. Brodsky RA, Young NS, Antonioli E, et al: Multicenter phase III study
36(2):145–152, 1970. of the complement inhibitor eculizumab for the treatment of patients
8. Rother RP, Bell L, Hillmen P, et al: The clinical sequelae of intravascular with paroxysmal nocturnal hemoglobinuria. Blood 111(4):1840–1847,
hemolysis and extracellular plasma hemoglobin: a novel mechanism of 2008.
human disease. JAMA 293(13):1653–1662, 2005. 21. Hillmen P, Muus P, Duhrsen U, et al: Effect of the complement inhibitor
9. Hill A, Kelly RJ, Hillmen P: Thrombosis in paroxysmal nocturnal eculizumab on thromboembolism in patients with paroxysmal nocturnal
hemoglobinuria. Blood 121(25):4985–4996, quiz 5105, 2013. hemoglobinuria. Blood 110(12):4123–4128, 2007.
10. Moyo VM, Mukhina GL, Garrett ES, et al: Natural history of parox- 22. DeZern AE, Dorr D, Brodsky RA: Predictors of hemoglobin response
ysmal nocturnal hemoglobinuria using modern diagnostic assays. Br J to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J
Haematol 126:133–138, 2004. Haematol 90:16–24, 2013.
11. Pu JJ, Hu R, Mukhina GL, et al: The small population of PIG-A mutant 23. Rondelli T, Risitano AM, Peffault de Latour R, et al: Polymorphism of
cells in myelodysplastic syndromes do not arise from multipotent hema- the complement receptor 1 gene correlates with hematological response
topoietic stem cells. Haematologica 97(8):1225–1233, 2012. to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
12. Hanaoka N, Nakakuma H, Horikawa K, et al: NKG2D-mediated Haematologica 99(2):262–266, 2014.
immunity underlying paroxysmal nocturnal haemoglobinuria and 24. Nishimura J, Yamamoto M, Hayashi S, et al: Genetic variants in C5 and
related bone marrow failure syndromes. Br J Haematol 146(5):538–545, poor response to eculizumab. N Engl J Med 370(7):632–639, 2014.
2009. 25. Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al: Allogeneic
13. Hillmen P, Lewis SM, Bessler M, et al: Natural history of paroxysmal stem cell transplantation in paroxysmal nocturnal hemoglobinuria.
nocturnal hemoglobinuria. N Engl J Med 333:1253–1258, 1995. Haematologica 97(11):1666–1673, 2012.
14. de Latour RP, Mary JY, Salanoubat C, et al: Paroxysmal nocturnal 26. Brodsky RA, Luznik L, Bolanos-Meade J, et al: Reduced intensity
hemoglobinuria: natural history of disease subcategories. Blood HLA-haploidentical BMT with post transplantation cyclophospha-
112(8):3099–3106, 2008. mide in nonmalignant hematologic diseases. Bone Marrow Transplant
15. Kelly RJ, Hill A, Arnold LM, et al: Long-term treatment with eculi- 42:523–527, 2008.
zumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and
improved survival. Blood 117(25):6786–6792, 2011.